The QT-interval and the new, atypical neuroleptic sertindole;QT-ZEIT-VERLANGERUNG UND DAS NEUE, ATYPISCHE NEUROLEPTIKUM SERTINDOL

Psychopharmakotherapie

Volumn 5, Issue 3, 1998, Pages 115-120

  Fritze, Jürgen ^a,b,d   Bandelow, Borwin ^c  

^a Verband der Privaten Krankenversicherung eV   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d NONE   (Germany)

Author keywords

Clozapine; ECG; Mortality; Neuroleptics; Olanzapine; QT interval; risperidone; Sertindole

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTINDOLE;

AGRANULOCYTOSIS; CEREBROVASCULAR ACCIDENT; ELECTROCARDIOGRAPHY MONITORING; EXTRAPYRAMIDAL SYNDROME; HEART ARREST; HEART FAILURE; HUMAN; LONG QT SYNDROME; MORTALITY; NEUTROPENIA; REVIEW; SCHIZOPHRENIA; SUICIDE; TORSADE DES POINTES;

EID: 0031690533     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Baker B, Dorian P, Sandor P, Shapiro C, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 1997;17:15-21.
2. Barnett AA. Safety concerns over antipsychotic drug, sertindole. Lancet 1997;348:256.
3. Beasley CM, Tollefson GD Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58:13-7.
4. Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995;33:199-204.
5. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: A meta-analysis. Int Clin Psychopharmacol 1995;10:207-13.
6. Di Salvo TG, O'Gara PT. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol 1995;18:285-90.
7. Drici MD, Wang WX, Woosley RL. Comparison of risperidone, olanzapine and sertindole on QT interval in isolated feline hearts. Congress Poster (1998).
8. Ereshefsky L. Pharmacokinetics and drug interactions: Update for new antipsychotics. J Clin Psychiatry 1996;57:12-25.
9. Flugelman MY, Tal A, Pollack S, et al. Psychotropic drugs and long QT syndromes: case reports. J Clin Psychiatry 1985;46:290-1.
10. Franz MR. Time for yet another QT correction algorithm? Bazett and beyond. J Am Coll Cardiol 1994;23:1554-6.
11. Fulop G, Phillips RA, Shapiro AK. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987;144:673-5.
12. Garson AJ. How to measure the QT interval - What is normal? Am J Cardiol 1993;72:14B-16B.
13. Guy S, Silke B. The electrocardiogram as a tool for therapeutic monitoring: A critical analysis. J Clin Psychiatry 1990;51:37-9.
14. Henderson RA, Lane S, Henry JA. Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose. Hum Exp Toxicol 1991;10:59-62.
15. Hewer W, Rost W, Gattaz F. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Eur Arch Psychiatry Clin Neurosci 1995;246:1-6.
16. Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 1997;157:2013-5.
17. Karjalainen J, Viitasalo M, Manttari M, Manninen V. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol 1994;23:1547-53.
18. Kiriike N, Maeda Y, Nishiwaki S, et al: Iatrogenic torsade de pointes induced by thioridazine. Biol Psychiatry 1987;22:99-103.
19. Kresse Hermsdorf M, Müller Oerlinghausen B. Tricyclic neuroleptic and antidepressant overdose: Epidemiological, electrocardiographic, and clinical features - A survey of 92 cases. Pharmacopsychiatry 1990;Suppl 23:17-22.
20. Kriwisky M, Perry GY, Tarchitsky D, Gutman Y, et al. Haloperidol-induced torsades de pointes. Chest 1990;98:482-4.
21. Lamarque V. Clozapine associated-agranulocytosis: A review of the international experience. Encephale 1996;22:35-6.
22. Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: A review of the literature. Pharmacotherapy 1997;17:531-7.
23. Metzger E, Friedman R. Prolongation of the corrected QT and Torsades de Pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993;13:128-32.
24. Möller HJ, Muller H, Borison RL, Schooler NR, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995;245:45-9.
25. Neue "atypische" Neuroleptika: Olanzapin (Zyprexa)/Sertindol (Serdolect). arznei-telegramm 1997:103-5.
26. Zum Risikoprofil von Sertindol (Serdolect). arznei-telegramm 1997:128.
27. Parsons M, Buckley NA. Overdose of antipsychotic drugs: Practical management guidelines. CNS Drugs 1997;7:427-41.
28. Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997;31:867-70.
29. Song F. Risperidone in the treatment of schizophrenia: A meta-analysis of randomized controlled trials. J Psychopharmacol 1997; 11:65-71.
30. Suessbrich H, Schonherr R, Heinemann SH, Attali B, et al. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997;120:968-74.
31. Tamminga CA, Mack RJ, Granneman GR, Silber CJ, et al. Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety. Int Clin Psychopharmacol 1997;12:S29-S35.
32. Tollefson GD, Sanger TM. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-74.
33. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
34. Van de Merwe TJ, Silverstone T, Ankier SI. Electrophysiological and haemodynamic changes with trazodone, amitriptyline and placebo in depressed out-patients. Curr Med Res Opin 1984;9:339-52.
35. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124:168-75.
36. Wagstaff AJ, Bryson HM. Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995;4:370-400.
37. Weaver MG. Olanzapine-pharmacology and clinical evaluation of a new atypical antipsychotic. J Serotonin Res 1997;4:145-57.
38. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, et al., and the Sertindole Study Group: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-91.